TY - JOUR KW - Bmi KW - Type 2 diabetes mellitus KW - Cohort study KW - fracture KW - sodium-glucose co-transporter-2 inhibitors AU - J. van Dalem AU - Cc Werkman AU - J. van den Bergh AU - B. Rossi AU - R. Viggers AU - R. Eastell AU - A. Burden AU - D. C AU - O. Klungel AU - Cgj Brouwers AU - Hm Driessen AD - Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands; Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre+, Maastricht, The Netherlands. Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands; Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre+, Maastricht, The Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht, The Netherlands. Department of internal medicine and NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, the Netherlands; Department of Internal Medicine, VieCuri Medical Center, Venlo, The Netherlands. Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands; Ministry for Health, Regulatory Affairs, Central Procurement Unit, Health-Central Procurement and Supplies, San Gwann, Malta. Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Steno Diabetes Center North Jutland, Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark. Mellanby Centre for Musculoskeletal Research, University of Sheffield, Sheffield, UK. Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Switzerland. Department of Internal Medicine and Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre+, Maastricht, The Netherlands. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht, The Netherlands. Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre+, Maastricht, The Netherlands; Department of Internal Medicine, division of Endocrinology and Metabolic Disease, Maastricht University Medical Centre+, Maastricht, The Netherlands. Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands; Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre+, Maastricht, The Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht, The Netherlands; Department of internal medicine and NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, the Netherlands. Electronic address: nikki.werkman@mumc.nl. AN - 35842030 BT - Diabetes Res Clin Pract DO - 10.1016/j.diabres.2022.109993 DP - NLM ET - 2022/07/17 LA - eng N1 - 1872-8227 van Dalem, Judith Cc Werkman, Nikki van den Bergh, Joop P Rossi, Bernardette Viggers, Rikke Eastell, Richard Burden, Andrea M DA Stehouwer, Coen Klungel, Olaf H Cgj Brouwers, Martijn Hm Driessen, Johanna Journal Article Ireland Diabetes Res Clin Pract. 2022 Jul 13:109993. doi: 10.1016/j.diabres.2022.109993. PY - 2022 SN - 0168-8227 EP - 109993 T2 - Diabetes Res Clin Pract TI - "Use of sodium-glucose co-transporter 2 inhibitors, changes in body mass index and risk of fracture: a population-based cohort study" ER -